Vanberra Signal

Invea Therapeutics

Curated by Signal

Developer of therapeutics for inflammatory gastrointestinal and hepatobiliary disorders

Overview

Developer of therapeutics for inflammatory gastrointestinal and hepatobiliary disorders. The company leverages artificial intelligence technology to accelerate and enhance drug discovery platforms for gastrointestinal disorders. The product pipeline includes INVA8001 for ulcerative colitis, and mastocytosis, and INVA8003 for inflammatory disorders.

Key facts

Founded
2021

Business model

Contact

More on Vanberra Signal

Members only

Competitors & similar companies

More Life Sciences Technology companies
  • Provider of next-generation precision genome engineering technology for development and manufacturing of therapeutics

    Life Sciences TechnologyUnited States
  • AI-driven theoretical and experimental systems biology to understand disease and develop therapeutics

    Life Sciences TechnologyLos Angeles, United States
  • Manufactures Diabetes monitoring device

    Life Sciences TechnologyWestlake Village, United States

About Invea Therapeutics

What does Invea Therapeutics do?

Developer of therapeutics for inflammatory gastrointestinal and hepatobiliary disorders.

Where is Invea Therapeutics headquartered?

Invea Therapeutics is headquartered in Guilford, United States.

When was Invea Therapeutics founded?

Invea Therapeutics was founded in 2021.

Which sector is Invea Therapeutics in?

Invea Therapeutics operates in Life Sciences Technology.

Who are Invea Therapeutics's competitors?

Companies similar to Invea Therapeutics include Komo Biosciences, Lyceum, and Decision Diagnostics.